NASDAQ:FGEN FibroGen (FGEN) Stock Price, News & Analysis → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free FGEN Stock Alerts $1.20 -0.04 (-3.23%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$1.20▼$1.3350-Day Range$0.98▼$2.6452-Week Range$0.33▼$19.47Volume1.31 million shsAverage Volume3.14 million shsMarket Capitalization$119.36 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get FibroGen alerts: Email Address FibroGen MarketRank™ Stock AnalysisAnalyst RatingReduce1.75 Rating ScoreUpside/Downside1,316.7% Upside$17.00 Price TargetShort InterestBearish6.96% of Shares Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$95,500 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.05) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.80 out of 5 starsMedical Sector229th out of 918 stocksPharmaceutical Preparations Industry98th out of 423 stocks 2.9 Analyst's Opinion Consensus RatingFibroGen has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageFibroGen has only been the subject of 1 research reports in the past 90 days.Read more about FibroGen's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.96% of the outstanding shares of FibroGen have been sold short.Short Interest Ratio / Days to CoverFibroGen has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in FibroGen has recently increased by 27.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFibroGen does not currently pay a dividend.Dividend GrowthFibroGen does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFibroGen has received a 74.19% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for the autoimmune system", "Clinical research services for cancer", and "Clinical research services for deficiency diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for FibroGen is -0.84. Previous Next 1.3 News and Social Media Coverage News SentimentFibroGen has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for FibroGen this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for FGEN on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added FibroGen to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, FibroGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $95,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.98% of the stock of FibroGen is held by insiders.Percentage Held by Institutions72.71% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about FibroGen's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for FibroGen are expected to grow in the coming year, from ($1.05) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of FibroGen is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of FibroGen is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about FibroGen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceCrypto Pioneer Says: “The last crypto bull market has begun.”Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble.Click here if you’d like to learn more about these five cryptos… About FibroGen Stock (NASDAQ:FGEN)FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Read More FGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FGEN Stock News HeadlinesMay 11, 2024 | americanbankingnews.comFibroGen, Inc. (NASDAQ:FGEN) Expected to Post Q2 2024 Earnings of ($0.24) Per ShareMay 10, 2024 | americanbankingnews.comBrokers Issue Forecasts for FibroGen, Inc.'s Q1 2025 Earnings (NASDAQ:FGEN)May 8, 2024 | finance.yahoo.comFibroGen First Quarter 2024 Earnings: Beats ExpectationsMay 8, 2024 | americanbankingnews.comFibroGen (NASDAQ:FGEN) Share Price Crosses Above 50 Day Moving Average of $1.70May 7, 2024 | msn.comFibroGen Shares Climb On Strong Q1 SalesMay 7, 2024 | finance.yahoo.comFibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call TranscriptMay 7, 2024 | markets.businessinsider.comGoldman Sachs Remains a Sell on FibroGen (FGEN)May 7, 2024 | finance.yahoo.comFibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 7, 2024 | globenewswire.comFibroGen to Participate in Upcoming Investor ConferencesMay 6, 2024 | msn.comFGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | finance.yahoo.comFibroGen Reports First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comFibroGen Reports First Quarter 2024 Financial ResultsMay 5, 2024 | markets.businessinsider.comHere's what Wall Street expects from FibroGen's earningsMay 3, 2024 | msn.comFibroGen Q1 2024 Earnings PreviewApril 29, 2024 | globenewswire.comFibroGen to Report First Quarter 2024 Financial ResultsApril 24, 2024 | finance.yahoo.comFibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual MeetingApril 24, 2024 | globenewswire.comFibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual MeetingApril 17, 2024 | msn.comFibroGen (FGEN) Price Target Increased by 40.00% to 1.79April 3, 2024 | markets.businessinsider.comFibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The LandscapeApril 3, 2024 | msn.comFibroGen falls after early-stage data for prostate cancer drugApril 3, 2024 | markets.businessinsider.comFibroGen (FGEN) Gets a Sell from Goldman SachsApril 2, 2024 | globenewswire.comFibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate CancerMarch 26, 2024 | globenewswire.comFibroGen to Present at 23rd Annual Needham Virtual Healthcare ConferenceMarch 20, 2024 | investorplace.com3 Nightmare Nasdaq Stocks Not Worth Holding Another DayMarch 11, 2024 | finanznachrichten.deFibroGen, Inc.: FibroGen Appoints Deyaa Adib, M.D. as Chief Medical OfficerSee More Headlines Receive FGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today5/18/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FGEN CUSIPN/A CIK921299 Webwww.fibrogen.com Phone(415) 978-1200Fax415-978-1902Employees486Year FoundedN/APrice Target and Rating Average Stock Price Target$17.00 High Stock Price Target$32.00 Low Stock Price Target$2.00 Potential Upside/Downside+1,316.7%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-284,230,000.00 Net Margins-143.57% Pretax Margin-145.04% Return on EquityN/A Return on Assets-46.06% Debt Debt-to-Equity RatioN/A Current Ratio1.41 Quick Ratio1.27 Sales & Book Value Annual Sales$147.75 million Price / Sales0.81 Cash FlowN/A Price / Cash FlowN/A Book Value($2.09) per share Price / Book-0.57Miscellaneous Outstanding Shares99,470,000Free Float97,504,000Market Cap$119.36 million OptionableOptionable Beta0.88 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Thane Wettig (Age 59)CEO & Director Comp: $941.79kMr. Juan Graham (Age 47)Senior VP & CFO Comp: $892.49kMs. Christine L. Chung (Age 56)Senior Vice President of China Operations Comp: $915.36kDr. Barry A. Berkowitz Ph.D.FounderDr. John J. Hunter Ph.D. (Age 61)Chief Scientific Officer David DeLuciaVice President of Corporate FP&A and Investor RelationsMr. Michael D. Lowenstein J.D.Ph.D., Chief Legal OfficerMs. Tricia StewartChief People OfficerMr. Kirk A. Christoffersen MBA (Age 55)Chief Business Officer Dr. Rahul Rajan Kaushik Ph.D.Senior Vice President of Pharmaceutical Development, Technical Operations & ManufacturingMore ExecutivesKey CompetitorsAdageneNASDAQ:ADAGImmunicNASDAQ:IMUXAbeona TherapeuticsNASDAQ:ABEORezoluteNASDAQ:RZLTCoya TherapeuticsNASDAQ:COYAView All CompetitorsInsiders & InstitutionsJacobs Levy Equity Management Inc.Sold 281,898 shares on 5/16/2024Ownership: 2.219%Public Employees Retirement System of OhioSold 56,407 shares on 5/15/2024Ownership: 0.121%Alpine Global Management LLCBought 10,752 shares on 5/15/2024Ownership: 0.011%Delap Wealth Advisory LLCBought 11,406 shares on 5/14/2024Ownership: 0.011%Acadian Asset Management LLCBought 34,937 shares on 5/10/2024Ownership: 2.517%View All Insider TransactionsView All Institutional Transactions FGEN Stock Analysis - Frequently Asked Questions Should I buy or sell FibroGen stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" FGEN shares. View FGEN analyst ratings or view top-rated stocks. What is FibroGen's stock price target for 2024? 4 analysts have issued 1 year target prices for FibroGen's stock. Their FGEN share price targets range from $2.00 to $32.00. On average, they expect the company's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 1,316.7% from the stock's current price. View analysts price targets for FGEN or view top-rated stocks among Wall Street analysts. How have FGEN shares performed in 2024? FibroGen's stock was trading at $0.8863 on January 1st, 2024. Since then, FGEN stock has increased by 35.4% and is now trading at $1.20. View the best growth stocks for 2024 here. When is FibroGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our FGEN earnings forecast. How were FibroGen's earnings last quarter? FibroGen, Inc. (NASDAQ:FGEN) issued its earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.15. The biopharmaceutical company earned $27.14 million during the quarter, compared to the consensus estimate of $40 million. What other stocks do shareholders of FibroGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ). When did FibroGen IPO? FibroGen (FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers. Who are FibroGen's major shareholders? FibroGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.47%), Acadian Asset Management LLC (2.52%), Jacobs Levy Equity Management Inc. (2.22%), Assenagon Asset Management S.A. (0.43%), BNP Paribas Financial Markets (0.14%) and Public Employees Retirement System of Ohio (0.12%). Insiders that own company stock include Benjamin Cravatt, Christine Chung, Enrique A Conterno, James A Schoeneck, Jeffrey William Henderson, Juan Graham, Mark Eisner, Pat Cotroneo, Thane Wettig and Thomas F Kearns Jr. View institutional ownership trends. How do I buy shares of FibroGen? Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FGEN) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaWhat’s Really Next for America…Porter & Company[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
